These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29175747)

  • 21. Comprehensive impurity profiling of nutritional infusion solutions by multidimensional off-line reversed-phase liquid chromatography × hydrophilic interaction chromatography-ion trap mass-spectrometry and charged aerosol detection with universal calibration.
    Schiesel S; Lämmerhofer M; Lindner W
    J Chromatogr A; 2012 Oct; 1259():100-10. PubMed ID: 22284534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation, structure characterization and quantification of related impurities in asperosaponin VI.
    Ji D; Liu YF; Wang QH; Zhang CF; Yang ZL
    Chin J Nat Med; 2013 Jul; 11(4):419-26. PubMed ID: 23845554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Speciation of antimony in injectable drugs used for leishmaniasis treatment (Glucantime®) by HPLC-ICP-MS and DPP.
    Séby F; Gleyzes C; Grosso O; Plau B; Donard OF
    Anal Bioanal Chem; 2012 Dec; 404(10):2939-48. PubMed ID: 23052871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification, Characterization, Synthesis and Quantification of Related Impurities of Liguzinediol.
    Cheng D; Zhou Y; Li W; Shan CX; Chai C; Cui XB; Kang B; Wang TL; Wen HM
    J Chromatogr Sci; 2015 Sep; 53(8):1280-8. PubMed ID: 25680683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solution degradant of mirabegron extended release tablets resulting from a Strecker-like reaction between mirabegron, minute amounts of hydrogen cyanide in acetonitrile, and formaldehyde in PEG during sample preparation.
    Lin J; Huang T; Feng M; Li D; Zhao D; Wang J; Jin J; Zhu W; Li M
    J Pharm Biomed Anal; 2019 May; 168():181-188. PubMed ID: 30818256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination and quantification of related substances and degradation products in bictegravir by full factorial design evaluated HPLC and mass spectrometry.
    Kumar SRJ; Rao VK; Katari NK; Jyothi NS; Kowtharapu LP
    Anal Methods; 2023 Mar; 15(10):1274-1285. PubMed ID: 36852477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automated peak tracking for comprehensive impurity profiling in orthogonal liquid chromatographic separation using mass spectrometric detection.
    Xue G; Bendick AD; Chen R; Sekulic SS
    J Chromatogr A; 2004 Oct; 1050(2):159-71. PubMed ID: 15508308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of RP UPLC-TOF/MS, stability indicating method for omeprazole and its related substances by applying two level factorial design; and identification and synthesis of non-pharmacopoeial impurities.
    Jadhav SB; Kumar CK; Bandichhor R; Bhosale PN
    J Pharm Biomed Anal; 2016 Jan; 118():370-379. PubMed ID: 26600119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the utility of ion mobility separation in combination with high-pressure liquid chromatography/mass spectrometry to facilitate detection of trace impurities in formulated drug products.
    Eckers C; Laures AM; Giles K; Major H; Pringle S
    Rapid Commun Mass Spectrom; 2007; 21(7):1255-63. PubMed ID: 17340559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.
    Nageswara Rao R; Narasa Raju A; Narsimha R
    J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of acetol in common pharmaceutical excipients using LC-MS.
    Beilin E; Baker LJ; Culbert P; Toltl NP
    J Pharm Biomed Anal; 2008 Jan; 46(2):316-21. PubMed ID: 18054457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impurity profiling of dapsone using gradient HPLC method.
    Leistner A; Holzgrabe U
    J Pharm Biomed Anal; 2021 May; 198():113982. PubMed ID: 33657522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The application of gas chromatography/atmospheric pressure chemical ionisation time-of-flight mass spectrometry to impurity identification in Pharmaceutical Development.
    Bristow T; Harrison M; Sims M
    Rapid Commun Mass Spectrom; 2010 Jun; 24(11):1673-81. PubMed ID: 20486265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
    Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
    J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impurity profiling of N,N'-ethylenebis-l-cysteine diethyl ester (Bicisate).
    Wahl O; Cleynhens J; Verbruggen AM; Holzgrabe U
    J Pharm Biomed Anal; 2018 Feb; 150():132-136. PubMed ID: 29223061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impurity profile tracking for active pharmaceutical ingredients: case reports.
    Zhou L; Mao B; Reamer R; Novak T; Ge Z
    J Pharm Biomed Anal; 2007 Jun; 44(2):421-9. PubMed ID: 17142001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of Peroxide Impurities in Povidone on the Stability of Selected β-Blockers with the Help of HPLC.
    Prachi S; Komal C; Priti MJ
    AAPS PharmSciTech; 2017 Oct; 18(7):2410-2417. PubMed ID: 28155135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
    Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
    J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel process related impurity and forced degradation study of synthetic wogonin: development of a liquid chromatographic method for purity control.
    Xia Y; Wu C; Liu W; Feng F; Li Z
    J Pharm Biomed Anal; 2012 Dec; 71():168-72. PubMed ID: 22906689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry.
    Wu CS; Tong YF; Wang PY; Wang DM; Wu S; Zhang JL
    Rapid Commun Mass Spectrom; 2013 May; 27(9):971-8. PubMed ID: 23592199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.